Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.77 +1.33 (+2.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,373,190
Open 52.72
Bid (Size) 53.50 (200)
Ask (Size) 54.00 (100)
Prev. Close 52.44
Today's Range 52.10 - 54.27
52wk Range 30.04 - 78.48
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026? ↗
There are some risks to consider before jumping on the bandwagon. 
Via The Motley Fool

Performance

YTD
N/A
N/A
1 Month
-4.0%
-4.0%
3 Month
-20.6%
-20.6%
6 Month
+5.0%
+5.0%
1 Year
+29.8%
+29.8%

More News

Read More
News headline image
The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy
Via PredictStreet
Topics Economy
Retail Bulls Call CRISPR ‘Criminally Undervalued’ After Gene-Editing Breakthrough Cuts Cholesterol By 70% ↗
Via Stocktwits
News headline image
Is CRISPR Therapeutics Stock Yesterday's News? ↗
Via The Motley Fool
News headline image
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗
Via The Motley Fool
News headline image
Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026? ↗
Via The Motley Fool
News headline image
2 Growth Stocks to Invest $1,000 in Right Now ↗
Via The Motley Fool
News headline image
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
From USA News Group
Via GlobeNewswire
News headline image
2 Monster Stocks in the Making to Buy and Hold ↗
Via The Motley Fool
News headline image
12 Days of Investing: My Top 12 Stocks to Buy Before 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Healthcare Stocks to Buy Ahead of the New Year ↗
Via The Motley Fool
News headline image
2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗
Via The Motley Fool
News headline image
Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% ↗
Via The Motley Fool
Topics ETFs
News headline image
The Best Stocks to Buy With $1,000 Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence Energy
News headline image
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential ↗
Via The Motley Fool
News headline image
Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results
Via MarketMinute
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Via The Motley Fool
News headline image
1 Underrated Stock That Could Soar by 58%, According to Wall Street ↗
Via The Motley Fool
News headline image
The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗
Via Benzinga
News headline image
Why Gene-Editing Giants Crispr And Intellia Just Surged ↗
Via Investor's Business Daily
Topics Death
News headline image
Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗
Via Investor's Business Daily
Topics Death
News headline image
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property

Frequently Asked Questions

Is CRISPR Therapeutics AG - Common Shares publicly traded?
Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.
What exchange does CRISPR Therapeutics AG - Common Shares trade on?
CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?
The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market
What is the current price of CRISPR Therapeutics AG - Common Shares?
The current price of CRISPR Therapeutics AG - Common Shares is 53.77
When was CRISPR Therapeutics AG - Common Shares last traded?
The last trade of CRISPR Therapeutics AG - Common Shares was at 01/02/26 04:00 PM ET
What is the market capitalization of CRISPR Therapeutics AG - Common Shares?
The market capitalization of CRISPR Therapeutics AG - Common Shares is 4.24B
How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?
CRISPR Therapeutics AG - Common Shares has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.